May 5, 2015
PET-CT (PET) rather than contrast-enhanced CT scanning should be considered the new gold standard for response assessment after first-line rituximab therapy for high-tumor burden follicular lymphoma (FL), a pooled analysis of a central review in three multicenter studies indicated.
"Post-induction PET-CT status is strongly predictive of both progression-free and overall survival," Judith Trotman, Clinical Associate Professor of Medicine, Concord Clinical School, Sydney, and colleagues wrote online in The Lancet Haematology.
In the study, the 4-year progression-free survival was 23% in PET-positive patients and 63% in PET-negative patients. Overall survival was 87% and 97%, respectively.